Article info

Download PDFPDF

698 A phase 2 study of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) (SABRCURE trial)
Free

Authors

Citation

Chen M, Ma H, Du X, et al
698 A phase 2 study of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) (SABRCURE trial)

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.